 Nina Mikkilineni
Concepts (63)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rhabdoid Tumor | 1 | 2022 | 80 | 0.740 |
Why?
| | Sarcoma | 1 | 2022 | 137 | 0.710 |
Why?
| | Kidney Neoplasms | 3 | 2018 | 324 | 0.290 |
Why?
| | Pubic Bone | 1 | 2022 | 4 | 0.200 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2022 | 17 | 0.200 |
Why?
| | Carcinoma, Renal Cell | 2 | 2014 | 168 | 0.200 |
Why?
| | Nephrolithiasis | 1 | 2021 | 10 | 0.190 |
Why?
| | Kidney Calculi | 1 | 2021 | 30 | 0.190 |
Why?
| | Rhabdomyosarcoma | 1 | 2022 | 56 | 0.190 |
Why?
| | Urology | 1 | 2021 | 46 | 0.180 |
Why?
| | Disease-Free Survival | 1 | 2022 | 618 | 0.180 |
Why?
| | BCG Vaccine | 1 | 2019 | 18 | 0.170 |
Why?
| | Nephrolithotomy, Percutaneous | 1 | 2019 | 3 | 0.170 |
Why?
| | Organ Dysfunction Scores | 1 | 2019 | 39 | 0.160 |
Why?
| | Ablation Techniques | 1 | 2019 | 25 | 0.160 |
Why?
| | RNA, Neoplasm | 1 | 2018 | 80 | 0.150 |
Why?
| | Prostatectomy | 1 | 2019 | 97 | 0.150 |
Why?
| | Consumer Health Information | 1 | 2019 | 47 | 0.150 |
Why?
| | Adaptive Immunity | 1 | 2019 | 154 | 0.150 |
Why?
| | DNA, Neoplasm | 1 | 2018 | 155 | 0.150 |
Why?
| | Shock, Septic | 1 | 2019 | 185 | 0.140 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2019 | 196 | 0.140 |
Why?
| | Liver Neoplasms | 1 | 2018 | 504 | 0.120 |
Why?
| | Internet | 1 | 2019 | 591 | 0.120 |
Why?
| | Genes, Neoplasm | 1 | 2014 | 20 | 0.110 |
Why?
| | Genomics | 1 | 2018 | 631 | 0.110 |
Why?
| | Communication | 1 | 2019 | 734 | 0.110 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1032 | 0.100 |
Why?
| | Prostatic Neoplasms | 1 | 2019 | 913 | 0.100 |
Why?
| | Models, Genetic | 1 | 2014 | 559 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2019 | 2122 | 0.080 |
Why?
| | Child | 2 | 2022 | 18401 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2159 | 0.070 |
Why?
| | Prognosis | 3 | 2019 | 3315 | 0.060 |
Why?
| | Neoplasms | 1 | 2018 | 2086 | 0.060 |
Why?
| | Female | 5 | 2022 | 59324 | 0.060 |
Why?
| | Humans | 9 | 2022 | 114045 | 0.060 |
Why?
| | Adolescent | 1 | 2022 | 17800 | 0.060 |
Why?
| | Mutation | 1 | 2014 | 3338 | 0.050 |
Why?
| | Male | 6 | 2022 | 55396 | 0.040 |
Why?
| | Administration, Intravesical | 1 | 2019 | 14 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2022 | 1117 | 0.040 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2018 | 11 | 0.040 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2019 | 68 | 0.040 |
Why?
| | Cancer Vaccines | 1 | 2019 | 137 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2019 | 438 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2021 | 12521 | 0.040 |
Why?
| | Patient Admission | 1 | 2019 | 175 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2021 | 632 | 0.030 |
Why?
| | Aged | 3 | 2019 | 18969 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2019 | 636 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2019 | 614 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 686 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2014 | 47 | 0.030 |
Why?
| | Genes, Tumor Suppressor | 1 | 2014 | 77 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2014 | 180 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 1815 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 4883 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1638 | 0.020 |
Why?
| | Child, Preschool | 1 | 2022 | 9114 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2014 | 2764 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2090 | 0.020 |
Why?
| | Middle Aged | 2 | 2014 | 26605 | 0.010 |
Why?
|
|
Mikkilineni's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|